Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)

An Open-Label, Randomized, Multicenter Study of the Safety, Tolerability, and Immunogenicity of Gardasil (V501) Given Concomitantly With REPEVAX™ in Healthy Adolescents 11-17 Years of Age

Data from this study are expected to demonstrate that Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine), when administered concomitantly with a combined diphtheria, tetanus, pertussis, and poliomyelitis vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines.

Inclusion Criteria:

• Must be healthy boys or girls, 11-17 years of age
• Must be a virgin with no intention of becoming sexually active during the study period
• Must have been properly vaccinated against diphtheria, tetanus, pertussis and polio

Exclusion Criteria:

• Must not have received a vaccine against diphtheria, tetanus, pertussis and polio in the past 5 years
• Must not have received any prior human papillomavirus (HPV) vaccine